Uncategorized

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced that the Annual Report for 2022 has been published.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, will present new data supporting GJB2-GT program candidate selection to address hearing loss related to mutations in the GJB2 gene during the Company’s R&D Day taking place , Thursday, April 6, 2023.

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from “Idea to IND”, announced it has entered into a collaboration agreement with ExeVir Bio.

Curis, Inc. announced that on March 31, 2023, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 135,450 shares of Curis common stock to a new employee, with a grant date of March 31, 2023.

Innate Pharma SA announced the filing of its 2022 Universal Registration Document for the year ending December 31, 2022 with the French market authority “Autorité des Marchés Financiers” on April 6, 2023.

Ochre Bio, an innovator in chronic liver disease medicine development, is pleased to announce the appointment of David Coughlan, PhD as VP of Translational Development and Chinwe Ukomadu, MD, PhD as an Observer on its Board of Directors.

  In today’s global economy, businesses are increasingly expanding beyond their home countries and hiring employees across borders. This presents a challenge when it comes to managing payroll, as each country has its own unique payroll regulations and tax requirements. That’s wher …

Last week, the Biden Administration filed a notice to appeal a federal court ruling that blocked the ACA mandate that requires health plans to fully cover preventative medical services like cancer, HIV and diabetes screenings.

The analysts expect Medtronic to “find a place in specific markets” that Intuitive is yet to dominate.

In a letter to Illumina shareholders, Icahn says the two companies “should be separated immediately” to protect the “long term growth prospects and viability of each.”